Ocera Therapeutics (OCRX) Receiving Somewhat Negative Press Coverage, Study Finds
News coverage about Ocera Therapeutics (NASDAQ:OCRX) has been trending somewhat negative this week, according to AlphaOne Sentiment. AlphaOne, a unit of Accern, identifies negative and positive media coverage by analyzing more than 20 million news and blog sources. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ocera Therapeutics earned a daily sentiment score of -0.22 on AlphaOne’s scale. AlphaOne also gave news articles about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an effect on the company’s share price in the immediate future.
A number of equities analysts have issued reports on OCRX shares. Aegis reaffirmed a “buy” rating and set a $3.00 price objective on shares of Ocera Therapeutics in a report on Wednesday, May 24th. HC Wainwright reiterated a “buy” rating and set a $4.00 target price on shares of Ocera Therapeutics in a research note on Wednesday, May 10th. Finally, Zacks Investment Research upgraded Ocera Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Thursday, March 23rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $3.90.
Shares of Ocera Therapeutics (NASDAQ:OCRX) opened at 0.96 on Friday. The company’s market capitalization is $25.45 million. The stock’s 50 day moving average price is $1.13 and its 200-day moving average price is $1.39. Ocera Therapeutics has a 1-year low of $0.52 and a 1-year high of $3.15.
Ocera Therapeutics (NASDAQ:OCRX) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.04. Ocera Therapeutics had a negative net margin of 4,416.26% and a negative return on equity of 148.87%. On average, equities analysts predict that Ocera Therapeutics will post ($1.10) EPS for the current year.
Ocera Therapeutics Company Profile
Ocera Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger.
Receive News & Ratings for Ocera Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocera Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.